Engie Says French Renewables Ban Could Endanger €5 Billion Plan
'This moratorium on wind and solar projects is both absurd and a disaster,' MacGrgegor said on Monday at an event on the Yeu island off the French Atlantic coast. 'We can't handle stop and go' in an industry that requires long-term planning, she said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
26 minutes ago
- Yahoo
Undiscovered European Gems With Strong Fundamentals July 2025
As European markets show signs of resilience, with the STOXX Europe 600 Index climbing 1.32% amidst easing trade tensions and potential economic stimulus from Germany, investors are increasingly turning their attention to small-cap stocks that may not yet be on the radar. In this environment, identifying companies with robust fundamentals—such as strong balance sheets and sustainable growth prospects—can provide valuable opportunities for those looking to navigate the complexities of today's market landscape. Name Debt To Equity Revenue Growth Earnings Growth Health Rating AB Traction NA 5.39% 5.24% ★★★★★★ Caisse Régionale de Crédit Agricole Mutuel Brie Picardie Société coopérative 26.90% 4.14% 7.22% ★★★★★★ Martifer SGPS 102.88% -0.23% 7.16% ★★★★★★ La Forestière Equatoriale NA -65.30% 37.55% ★★★★★★ ABG Sundal Collier Holding 8.55% -4.14% -12.38% ★★★★★☆ Evergent Investments 5.39% 9.41% 21.17% ★★★★☆☆ Darwin 3.03% 84.88% 5.63% ★★★★☆☆ Practic 5.21% 4.49% 7.23% ★★★★☆☆ Inversiones Doalca SOCIMI 15.57% 6.53% 7.16% ★★★★☆☆ MCH Group 124.09% 12.40% 43.58% ★★★★☆☆ Click here to see the full list of 326 stocks from our European Undiscovered Gems With Strong Fundamentals screener. Here we highlight a subset of our preferred stocks from the screener. Simply Wall St Value Rating: ★★★★☆☆ Overview: Caisse Régionale de Crédit Agricole Mutuel Loire Haute-Loire Société coopérative offers a range of banking products and services to diverse customer segments in France, with a market capitalization of approximately €579.37 million. Operations: CRLO generates revenue primarily from local banking in France (€234.80 million) and leasing activities (€151.14 million), with a smaller contribution from land-related operations (€1.13 million). With total assets of €15.2B and equity at €2.8B, Crédit Agricole Loire Haute-Loire stands out with its earnings growth of 14.9% over the past year, surpassing the industry average of 3.2%. The bank's liabilities are primarily low-risk customer deposits, making up 95% of its funding sources. However, it faces a challenge with a high level of bad loans at 3.2%, despite having a low allowance for these loans (82%). Trading at 29.1% below estimated fair value suggests potential upside if risks are managed effectively in this burgeoning financial landscape. Delve into the full analysis health report here for a deeper understanding of Caisse Régionale de Crédit Agricole Mutuel Loire Haute-Loire Société coopérative. Gain insights into Caisse Régionale de Crédit Agricole Mutuel Loire Haute-Loire Société coopérative's past trends and performance with our Past report. Simply Wall St Value Rating: ★★★★★☆ Overview: Olvi Oyj is a beverage company that manufactures and sells alcoholic and non-alcoholic beverages across Finland, Estonia, Latvia, Lithuania, Denmark, and Belarus with a market cap of €700.73 million. Operations: Olvi Oyj generates revenue primarily from its alcoholic beverages segment, which accounts for €659.34 million. The company's financial performance is highlighted by a notable net profit margin trend, reflecting efficiency in managing costs relative to its revenue streams. Olvi, a Finnish beverage company, has shown impressive earnings growth of 14.8% over the past year, outpacing the broader beverage industry's 0.7%. The firm is trading at an attractive value, estimated to be 73.6% below its fair value compared to peers and industry standards. While Olvi's debt-to-equity ratio rose from 4.8% to 7.1% in five years, it remains financially robust with more cash than total debt and positive free cash flow of €48.51 million as of September 2024. Additionally, recent board changes include Nora Hortling as Chair and Lasse Heinonen as Vice Chair, enhancing governance dynamics. Get an in-depth perspective on Olvi Oyj's performance by reading our health report here. Learn about Olvi Oyj's historical performance. Simply Wall St Value Rating: ★★★★☆☆ Overview: Norion Bank AB (publ) offers financial solutions to medium-sized corporates, real estate companies, merchants, and private individuals across Sweden, Germany, Norway, Denmark, Finland, and internationally with a market cap of SEK10.45 billion. Operations: Norion Bank's primary revenue streams are derived from real estate (SEK1.22 billion), consumer (SEK930 million), corporate (SEK827 million), and payments (SEK501 million) segments. Norion Bank, with total assets of SEK67.6B and equity of SEK9.5B, operates primarily on low-risk funding from customer deposits, which make up 93% of its liabilities. Despite a high level of bad loans at 21.2%, the bank's earnings grew by 7.2% over the past year, surpassing the industry average decline of -1.5%. Trading at a substantial discount to its estimated fair value by 70.1%, Norion offers good relative value compared to peers in the industry while maintaining high-quality earnings despite challenges such as a low allowance for bad loans at only 49%. Click here and access our complete health analysis report to understand the dynamics of Norion Bank. Gain insights into Norion Bank's historical performance by reviewing our past performance report. Get an in-depth perspective on all 326 European Undiscovered Gems With Strong Fundamentals by using our screener here. Are any of these part of your asset mix? Tap into the analytical power of Simply Wall St's portfolio to get a 360-degree view on how they're shaping up. Unlock the power of informed investing with Simply Wall St, your free guide to navigating stock markets worldwide. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ENXTPA:CRLO HLSE:OLVAS and OM:NORION. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
41 minutes ago
- Yahoo
IntegraGen: Sales of €2.5 Million in the First Half of 2025 and Cash Position of €2.1 Million
Sequencing activities at Évry down 31% Decrease in activities on the P2M microbiology platform operated on the Institut Pasteur site Free cash position of €2.1m at June 30, 2025, after a consumption of €0.9m in the first half. The cash situation at this rate of consumption may not allow the company to continue its activities without new financing beyond the first quarter of 2026 EVRY, France, July 02, 2025--(BUSINESS WIRE)--Regulatory News: IntegraGen (FR0010908723 – ALINT – Eligible PEA PME), an OncoDNA company specializing in the genomics of cancer and rare genetic diseases, which performs interpretable genomic analyses for academic and private laboratories, announces today its unaudited sales for the first half of 2024. Sales for the first half came to €2,540K, down 34% compared with the first half of 2024 on a like-for-like basis (excluding revenues from the SeqOIA platform), contrary to expectations of weak growth, comparable to that of 2024, as announced by the Company in its press release dated April 29, 2025, on its results for the 2024 financial year. This decline is the result of reduced activity of over 40% on the Institut Pasteur's Mutualized Microbiology platform, linked to the drop in epidemiological sequencing, as well as to the decline in projects carried out on the Evry genomics platform, down by around 31%. This decline is the result of delays in the start-up of two major projects, the first samples of which were received by the company in May, as well as a general slowdown in research projects for academic and hospital customers. The company believes that the second half of the year, with the acceleration of major projects (notably UMBRELLA) and improved funding conditions for public research, should enable the situation to improve from the third quarter onwards. As of June 30th, available cash, including the remainder on the loan granted to the parent company OncoDNA and repaid over the course of 2025, stood at €2.1m. The company used up €0.9m of cash in the first half of 2025, and at this rate may not have enough cash to ensure its financing for the next 12 months. In this context, the company is exploring all strategic options to improve its situation and expects to reduce cash consumption in the second half of the year through the reduction of operating costs, the launch of services for several existing customers, external sources of financing, a resumption of customer research projects, as well as the expected upturn in customers' research budgets. Given the high level of uncertainty surrounding public research funding, the Company is not maintaining its revenue growth forecasts for 2025. Bernard Courtieu, Chief Executive Officer of IntegraGen, comments: "The first half of the year has been extremely difficult, with both a sharp drop in academic and hospital research projects, linked to a reduction in public research financing, as well as a reduction in the budgets of several biotech companies in a sector affected by the general economic climate. Despite several successes such as the UMBRELLA project, whose operational launch was announced last month, IntegraGen needs to find new sources of funding to be able to ensure the continuity of its operations." Investors are invited to carefully read section 4.2 of the 2024 Management Report on "Principal risks and uncertainties facing the Company". Financial results for the first half of 2025 will be published in October. ABOUT INTEGRAGEN IntegraGen is an OncoDNA group company specializing in the genomics of cancer and rare genetic diseases. Backed by highly competent and qualified teams, IntegraGen is a leading player in DNA sequencing services and genomic data interpretation software. The company runs one of the largest NGS labs in France and operates for research institutes of excellence. As part of OncoDNA group, IntegraGen leverages the power of next generation sequencing with the mission of delivering the promise of precision medicine to patients. IntegraGen has about 40 employees and generated €8.5 million of turnover in 2024. Based in France, IntegraGen is part of the Belgian OncoDNA group present in Spain, UK, Germany and works with an international network of 35 distributors. The Group also provides biomarker testing and clinical interpretation tools to guide treatment and monitoring of late stage solid tumors and accelerate the development of new cancer drugs. IntegraGen is listed on Euronext Growth in Paris (ISIN: FR0010908723 – Mnemo: ALINT – Eligible PEA- PME). View source version on Contacts IntegraGen Bernard COURTIEUDirecteur GénéralVirginie De CosterDirecteur Administratif et Financiercontact@ Tél. : +33 (0)1 60 91 09 00 NewCap Relations Investisseurs Louis-Victor DELOUVRIERintegragen@ Tél. : +33 (0)1 44 71 98 53 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
44 minutes ago
- Yahoo
Why AES Corporation Stock Flopped Today
Many high-level politicians are proving to be no friends of the renewable energy industry. A clutch of them are now proposing that certain green energy assets be subject to fresh taxes in the One, Big, Beautiful Bill. 10 stocks we like better than The AES Corporation › The latest political developments in Washington, D.C., cast a shadow over renewable energy stocks on Monday. Reacting to news that very late-stage revisions to the One, Big, Beautiful Bill would impose a new set of taxes on the solar and wind segments, investors traded out of energy companies involved in those niches. One victim was the renewables-embracing AES Corporation (NYSE: AES), whose shares took it on the chin with a nearly 2% decline on the day. Meanwhile, the benchmark S&P 500 index closed Monday 0.5% higher. In an attempt to get the controversial bill into sufficient shape to maximize its chances for passing, Republican senators on Monday introduced taxes for certain wind and solar projects. Earlier versions of the bill only brought forward the expiration dates of current tax incentives for these forms of energy. As of midafternoon Monday, senators were to discuss and vote on numerous amendments to the bill, including the proposed renewables taxes. Although AES is not a pure-play renewable energy company, it has enthusiastically embraced such forms of power generation. At the moment, 52% of the company's total deployed power assets fall under the renewable umbrella. That diversification is likely a main reason why the investor reaction to the news wasn't more drastically negative. If those proposed new solar and wind levies make their way into the final bill and it's passed, AES will still have plenty of traditional power assets that won't (at least for now) be subject to them. What's more concerning for the long term is that, like many old-line power companies making a shift to green energy, AES has poured billions of dollars into developing renewable solutions. The proposed withdrawal of tax incentives in the bill were concerning enough; the company could be looking at rather significant tax bills once its in-development projects come onstream. Before you buy stock in The AES Corporation, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and The AES Corporation wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $713,547!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $966,931!* Now, it's worth noting Stock Advisor's total average return is 1,062% — a market-crushing outperformance compared to 177% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 30, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Why AES Corporation Stock Flopped Today was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
